UNSPSC 51282905: Besifloxacin

This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BFE2NBZ7NX. European Medicines Agency schedules Besifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33064. Besifloxacin generally arises in the molecular formula C19H21CLFN3O3. The term BESIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60.) Most nations schedule besifloxacin under HS 29334900 and SITC 51575.

As of Q4 2014, BESIFLOXACIN remains the US FDA Preferred Term for this commodity. Besifloxacin bears US NLM identifiers UMLS ID C2351042 and NCI Concept Code C83553. SMILES: C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.

UNSPSC 51282905 Besifloxacin (Commodity) does not reflect recent state and local procurement activity—the two most recent opportunities tagged to this code involve naloxone and drug deactivation systems, and a piggyback pharmaceutical warehouse contract for doxycycline and ciprofloxacin, neither of which are besifloxacin products. The code shows a mismatch between its nominal scope (a specific ophthalmic antibiotic) and the actual purchases being made under it in state and local procurement.

The limited activity visible under this code involves health and safety goods sourced through competitive bidding and cooperative purchasing vehicles. Seminole County, Florida issued an IFB (Bid Number IFB60459723LAS) on June 30, 2026, to procure naloxone and drug deactivation systems annually through competitive bidding, with quarterly deliveries and responses due July 26, 2026. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract (Solicitation Number 26482DPHPREPDB53392) through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotic tablets valued at $2,999,999.11 over the contract term. No recent opportunities naming besifloxacin specifically appear in the available records, and the issuing bodies shown—a county health department and a state health agency—do not suggest concentrated demand under this code. Geographic activity is sparse and limited to Florida and Illinois based on the posted records.